^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2023
    Title:

    3060 Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

    Published date:
    11/02/2023
    Excerpt:
    Despite the presence of BV-refractory disease, 4 cycles of BV and nivolumab is tolerable and associated with encouraging efficacy in patients with heavily treated CD30+ lymphoma.
    Trial ID:
    RG1713010